The global mRNA vaccines market for non-COVID applications is projected to grow at a 109% compound annual growth rate from $9 million in 2026 to $7.04 billion by 2035. Market expansion is driven by advancing clinical pipelines, diversification into influenza, RSV, oncology and next-generation RNA technologies, with over 100 mRNA-based cancer candidates under investigation. Influenza is expected to become the leading indication by 2035, while North America remains the largest regional market.

Artificial intelligence is transforming blood cancer drug discovery and development, with over $2 billion in investment from major biotech and pharma companies. AI is reducing clinical trial timelines by up to 50%, improving patient selection, and enabling next-generation therapies like CAR-T and antibody-drug conjugates. North America leads with 40% of global market share, while Asia-Pacific emerges as a significant growth region.

The global influenza vaccine market was valued at US$8.96 billion in 2024 and is projected to reach US$13.32 billion by 2030, growing at a 7% CAGR. Market expansion is driven by rising public health awareness, an aging population, government immunization programs, and increased R&D investment. Quadrivalent and inactivated vaccines lead the market, while cell-based technologies and pediatric segments show fastest growth. Key players include GlaxoSmithKline, Pfizer, Sanofi, Moderna, and others.

Sanofi reported strong Q2 2026 results with 17.8% sales growth at constant exchange rates and business EPS of €2.09, leading to upgraded 2026 guidance. However, the company announced discontinuation of clinical development for amlitelimab in moderate-to-severe atopic dermatitis.

Sanofi reported strong Q2 2026 results with 17.8% sales growth at constant exchange rates and business EPS of €2.09, leading to an upgrade of full-year 2026 guidance. However, the company announced discontinuation of clinical development for amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis.

Sanofi, a French pharmaceutical company, is recommended as a promising dividend stock with a 5.6% yield that approaches 11% when including stock buybacks. The company is growing well with its flagship drug Dupixent showing 31% year-over-year sales growth, and the stock trades at an attractive valuation with a forward P/E ratio of 9, well below its five-year average.

Sanofi has decided to halt clinical development of amlitélimab, a monoclonal antibody for moderate-to-severe atopic dermatitis, and will not submit it for regulatory approval worldwide. The company determined that efficacy and safety data do not support further development, as the drug would not represent a significant improvement over standard treatments. While the Phase 3 ESTUARY extension study showed long-term clinical response maintenance and acceptable safety profile, Sanofi maintains its 2026 financial guidance.

Sanofi has discontinued clinical development of amlitelimab, an OX40-ligand monoclonal antibody, for moderate-to-severe atopic dermatitis. The company determined that efficacy and safety evidence does not support further development, as the drug would not represent a meaningful improvement over current standard of care. The decision does not impact 2026 financial guidance. Amlitelimab development continues in celiac disease with results expected in H2 2026.

Scribe Therapeutics, a clinical-stage biotech company focused on in vivo CRISPR technologies, priced its IPO at $15 per share, raising $128.7 million from 8.58 million shares. The company will begin trading on Nasdaq under ticker SCTX on July 24, 2026. Additionally, Sanofi agreed to purchase 500,000 shares in a concurrent private placement at the same price.

The global antiparasitic drugs market is projected to grow from USD 23.30 billion in 2026 to USD 30.98 billion by 2032 at a 4.88% CAGR. Growth is driven by persistent parasitic disease burden, drug resistance, climate-sensitive vector transmission, and public health programs. Key opportunities include resistance-ready combination therapies, pediatric formulations, AI-enabled discovery, and diagnostics-linked prescribing, with Africa and Asia-Pacific leading endemic demand.

ResearchAndMarkets.com released a comprehensive report analyzing over 1,859 clinical-stage pharmaceutical and biotechnology partnership deals announced since 2020. The report provides detailed financial terms, deal structures, contract documents, and insights into negotiation dynamics for clinical-stage drug development collaborations, serving as a benchmarking resource for biopharma dealmakers.

The global autoimmune disease therapeutics market is projected to grow from USD 80.54 billion in 2025 to USD 137.85 billion by 2035, with a CAGR of 5.52%. Growth is driven by rising prevalence of autoimmune diseases, adoption of biologics, JAK inhibitors, monoclonal antibodies, and precision medicine technologies. North America leads with 39.96% market share, while Asia-Pacific shows the fastest growth at 6.28% CAGR.